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Abstract35
The present work aimed at studying the interaction between insulin and SiNP surfaced 36
with mucoadhesive polymers (chitosan, sodium alginate or polyethylene glycol) and the37
evaluation of their biocompatibility with HepG2 and Caco-2 cell lines, which mimic in 38
vivo the target of insulin-loaded nanoparticles upon oral administration. Thus, a39
systematic physicochemical study of the surface-modified insulin-silica nanoparticles 40
(Ins-SiNP) using mucoadhesive polymers has been described. The surfacing of41
nanoparticle involved the coating of silica nanoparticles (SiNP) with different 42
mucoadhesive polymers, to achieve high contact between the systems and the gut 43
mucosa to enhance the oral insulin bioavailability. SiNP were prepared by a modified 44
Stöber method at room temperature via hydrolysis and condensation of tetraethyl 45
orthosilicate (TEOS). Interaction between insulin and nanoparticles was assessed by 46
differential scanning calorimetry (DSC), X-ray and Fourier-transform infrared (FTIR) 47
studies. The high efficiency of nanoparticles’ coating resulted in more stable system. 48
FTIR spectra of insulin-loaded nanoparticles showed amide absorption bands which are 49
characteristic of α-helix content. In general, all developed nanoparticles demonstrated50
high biocompatible, at the tested concentrations (50 – 500 μg/mL), revealing no or low 51
toxicity in the two human cancer cell lines (HepG2 and Caco-2). In conclusion, the 52
developed insulin-loaded SiNP surfaced with mucoadhesive polymers demonstrated its 53
added value for oral administration of proteins.54
55
56
Keywords: silica nanoparticles,coated-SiNPs, insulin,mucoadhesive polymersHepG2 57
cell, Caco-2 cell58
59
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1.  Introduction61
62
The recent advances in the field of biotechnology has shown several innovative 63
strategies for protein drug delivery, exploiting non-invasive routes (e.g. oral [1, 2], nasal 64
[3], pulmonary [4, 5], buccal [6, 7] or transdermal [8]), to reach a better patient’s65
compliance in the treatment of diabetes. Among the proposed non-invasive alternatives, 66
the oral administration of insulin seems to be more convenient to the patient. Insulin 67
could be rapidly delivered in the liver through the portal circulation, after being 68
absorbed in the intestine and, thus, the hyperinsulinemia condition could be avoided [9]. 69
Nevertheless, the oral absorption of therapeutic proteins is hindered by several 70
difficulties, such as their high molecular weight and hydrophilicity, low pH of gastric 71
medium leading to protein denaturation and the presence of proteolytic enzymes that 72
can reduce or even abolish their performance in vivo [10].73
A promising strategy to improve the oral insulin bioavailability is to develop drug 74
delivery systems that protect the protein from metabolic degradation, as well as prolong 75
the gastrointestinal residence time, improving the absorption of the macromolecules 76
through the intestinal tract. Nanoparticles coated with selected mucoadhesive polymers 77
would be advantageous for oral delivery of therapeutic proteins. 78
Due to their high porosity, specific surface area, biocompatibility and ease of surface 79
functionalization, silica nanoparticles (SiNP) have been considered an excellent option 80
as delivery systems for proteins [11-14].The presence of residual silanol groups (Si-OH) 81
onto the silica surface triggers the reactive sites for its surface modification by specific82
organic groups [15]. 83
Based on these previous considerations, the purpose of the present study was to develop 84
and characterize an organic/inorganic hybrid system intended for the oral insulin 85
administration by combining the advantages of SiNP with the mucoadhesive properties 86
of selected hydrophilic polymers. In this work, SiNP were chosen as drug delivery 87
system for insulin, using chitosan (CH), sodium alginate (SA) or poly(ethylene glycol) 88
(PEG) as mucoadhesive polymers. Multifunctional polymers have been extensively 89
explored as matrix material in the development of mucosal drug delivery systems [16]. 90
Chitosan is a biocompatible polysaccharide which improves the penetration of 91
therapeutic proteins in the intestinal mucosa, because of the interaction of its amine 92
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groups with negatively charged mucin. Chitosan can increase the paracellular 93
permeability by affecting the structure of proteins associated to the tight junctions [17]. 94
Alginate is a biopolymer also showing bioadhesive properties. Unlike chitosan, alginate 95
prolongs the drug residence time in the mucosa due to the presence of numerous 96
carboxyl groups, leading to a strong bioadhesive interaction by hydrogen bonds 97
between anionic polymer and mucin [18]. 98
PEG-coated nanoparticles have also been investigated for oral administration. It is 99
known that PEG coatings can stabilize the nanoparticles in the gastric and intestinal 100
fluids by steric hindrance, due to the inhibition of plasma protein adsorption [19]. In 101
addition, PEGs can promote the mucoadhesion by the penetration of their chains in the 102
intestinal mucosa [20]. 103
Despite the increased attractiveness of nanotechnology for biomedical applications, the 104
human exposure and environmental impact of the nanomaterials are also of great 105
concern. Recent studies show that intrinsic properties of nanoparticles, such as size, 106
shape and surface charge, can damage the cell membrane leading to changes of cell 107
morphology and stability [21]. Therefore, it is important to consider a balance between 108
the benefits and the potential hazards of nanomaterials when developing a suitable 109
system for the purpose of drug and targeting delivery.110
In the present study, the interaction between insulin and SiNP coated with different 111
mucoadhesive polymers was examined by X-ray diffraction, differential scanning 112
calorimetry (DSC) and Fourier transform infrared (FTIR) analyses. The 113
biocompatibility of different nanoparticles was evaluated in HepG2 and Caco-2 cell 114
lines, which mimic the in vivo the target of insulin-loaded SiNP upon oral115
administration.116
117
118
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2. Materials and methods119
120
2.1. Materials121
122
Tetraethyl orthosilicate (TEOS, 98%), NH3 25%, PEG with Mw of 6000 and 20000 Da 123
(PEG 6000; PEG 20000) were purchased from Merck (Darmstadt, Germany). Chitosan 124
low molecular weight (235 g/mol, deacetylation degree of 78.5 %), ethanol 99.9 %, 125
trehalose dehydrate and bovine serum albumin (BSA) were purchased from Sigma-126
Aldrich (Steinhein, Germany). Sodium alginate (198.11 g/mol) was purchased from 127
VWR Portugal (Carnaxide, Portugal). Solution of 100 IU/mL of human insulin 128
(Humulin® R) was purchased from Eli Lilly (Lisbon, Portugal). Dulbecco’s Modified 129
Eagle’s Medium (DMEM), foetal bovine serum (FBS), penicillin/streptomycin, L-130
glutamine, 0.05% tripsin-EDTA and AlamarBlue (AB) were purchased from Gibco131
(Alfagene, Invitrogen, Portugal). HepG2 (Human hepatocellular carcinoma cell line; 132
ATCC® Number: HB-8065 ™) were a gift from Professor Carlos Palmeira (CNC-UC, 133
Coimbra, Portugal) and Caco-2 (Human colon adenocarcinoma cell line) was purchased 134
from Cell Lines Service (CLS, Eppelheim, Germany). Ultra-purified water was obtained 135
from MiliQ Plus system (Milipore, Germany).136
137
2.2. Synthesis of nanoparticles138
139
Silica nanoparticles were synthesized at room temperature via hydrolysis and 140
condensation of TEOS under high shear homogenization (Ultra-Turrax, IKA, T25) 141
using NH3 as catalytic agent. The obtained nanoparticles were centrifuged and washed 142
with a mixture of ethanol and ultra-purified water (1:1, v/v) by 2 cycles at 12,000 rpm 143
for 5 min (Spectrafuge16M, Lambnet International, Inc.).144
For coating silica nanoparticles, a solution of chitosan (CH) (0.3%, w/v) at pH 4.5, or 145
sodium alginate (SA) (0.3% , w/v) at pH 4.5, or PEG 60002 or PEG 20000 (2%, w/v) at 146
pH 6.8 was added to the nanoparticles, stirred for 30 min and centrifuged as described 147
above. 148
For insulin association to SiNP, 1 mL of human insulin (100 IU/mL, pH 7.0) was added 149
to 10 mg of uncoated SiNP under gentle stirring (300 rpm) for 30 min into ice bath. 150
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For coated insulin-SNP, 1.0 mL of human insulin (100 IU/mL, pH 7.0) was dissolved in 151
2 mL of the hydrophilic polymer solutions, mixed for 30 min under magnetic stirring 152
and then added to SiNP (10 mg) under gentle stirring (300 rpm) for more 30 min into 153
ice bath. The nanoparticles were centrifuged at 5000 rpm for 5 min and the pellet was 154
freeze-dried during 24 h in the presence of trehalose (10 %, w/v).155
156
2.3. Differential Scanning Calorimetry (DSC) analysis157
158
Thermograms were obtained using a TA Instrument (New Castle, USA). Accurately, 5 159
mg of lyophilized nanoparticles were weighted in 40 μL aluminium pans. DSC scans 160
have been recorded from 25 to 350ºC at a heating constant rate of 10ºC/min under 161
purging of nitrogen at 20 mL/min using an empty pan as reference. Data were obtained 162
from the peaks areas using the TA software (TA Instrument). 163
164
2.4. Fourier Transform Infrared (FTIR) analysis165
166
FTIR-spectra were performed using a Shimadzu® Europe - Prestige-21 spectrometer. 167
Uncoated and coated nanoparticles containing insulin were gently mixed with a suitable 168
amount of micronized KBr powder and compressed into discs at a force of 10 kN using 169
a manual tablet presser. For each spectrum, a 128-scan interferogram was collected with 170
a 4 cm1 resolution in the mid-IR region at 25 °C.171
172
2.5. X-Ray studies173
174
X-Ray diffraction patterns of bulk materials and nanoparticles were performed using 175
Siemens D5000 diffractometer system (Siemens, Germany) with a copper anode(Cu-Kα176
radiation, λ = 0.1542 nm) at angles 2θ = 4-70º.177
178
2.6. Cell cultures and maintenance179
180
HepG2,a human hepatocellular carcinoma cell line, obtained from ATCC, was kindly 181
provided by Prof. Carlos Palmeira (CNC, UC, Portugal) and Caco-2, a human colorectal182
adenocarcinoma cell line, obtained from Cell Line Services, AG (Germany)were used 183
as cell models to perform the cytotoxicity assay of the different nanoparticles. HepG2 184
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and Caco-2 cells were maintained in DMEM (Dulbecco's Modified Eagle Medium)185
supplemented with 10 % (v/v) foetal bovine serum (FBS), antibiotics (100 U/mL of 186
penicillin and 100 µg/mL of streptomycin) and 1 mM L-glutamine in an atmosphere of 187
5% CO2 /95 % air, at 37 °C with controlled humidity. 188
189
2.7. In vitro cytotoxicity assay190
191
The cytotoxicity of nanoparticles was evaluated by comparing the proliferation rate and 192
viability of non-exposed HepG2 or Caco-2 cells(control) with exposed HepG2 or Caco-193
2 cells, to appropriate concentrations during defined periods of time (see below), using 194
the AB reduction method. 195
For the cytotoxicity assay cells were detached from the culture flaks with trypsin, 196
counted and seeded into 96-well microplates at a density of 5×104 cells/mL (100 197
L/well). Lyophilized nanoparticles were diluted in FBS-free culture media to various 198
concentrations, ranging from 50 to 500 µg/mL (0, 50, 200, 500 µg/mL). Then, 24 h after 199
seeding, the culture media was removed and replaced by media containing the 200
nanoparticles (at defined concentrations). For each concentration of nanoparticles, 201
microplates were placed in the incubator, and cells were exposed for 48 h. After the 202
exposure time, the media containing the nanoparticles (and the control) was removed 203
and replaced by FBS-free medium supplemented with 10 % (v/v) of AB. The 204
absorbance readings occurred about 4 h after AB addition, at 570 and 620 nm using a 205
Multiskan EX microplate reader (MTX Labsystems, USA). The percentage of AB 206
reduction was calculated according to the following equation:207
208
209
210
where,  is the molar extinction coefficient of oxidized AB at 570 nm,  is the 211
molar extinction coefficient of oxidized AB at 620 nm,  is the molar extinction 212
coefficient of reduced AB at 570 nm,  is the molar extinction coefficient of 213
reduced AB at 620 nm,  and  are the absorbance of test wells at 570 and 620 nm, 214
respectively, and  and are the absorbance of the negative control wells (media 215
plus AB but no cells) at 570 and 620 nm, respectively.216
217
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2.8. Statistical analysis218
219
Results are expressed in terms of cell viability as percentage of control (untreated cells), 220
and are a mean of three independent experiments (n=3) ± S.D (in each experiment, each 221
condition was tested in 8 replicate wells (octuplicates)). Statistically evaluation of data 222
was performed using a one-way analysis of variance (ANOVA) test. Bonferroni’s 223
Multiple Comparison test was carried out to compare the significance between the 224
different groups. A p-value < 0.05 was considered statistically significant.225
226
227
3. Results and discussions228
229
3.1. DSC analysis230
231
In this study, DSC was used to evaluate the influence of the selected coatings in SiNP. 232
Table 1 presents a summary of the peak temperature and enthalpies associated with each 233
peak for the various bulk materials and for the nanoparticles produced by sol-gel 234
technology. 235
Typical DSC thermograms of coated SiNP with sodium alginate, SiNP-SA, chitosan, 236
SiNP-CH, PEG 6000, SiNP-PEG 6000, and PEG 20000, SiNP-PEG 20000, are shown237
in Figure 1A (as denoted). Thermogram of sodium alginate depicted an endothermic 238
peak at 97 ºC followed by an exothermic transition at 239.74 ºC (Table 1). The 239
exothermic peaks attributed to a polymer were attributed to the degradation phenomena 240
due to depolymerization or oxidation reactions [22, 23].241
242
[Please, insert Table 1 near here]243
244
Upon coating of SiNP with SA (SiNP-SA), the endothermic peak was shifted to 139.91 245
°C associated to an enthalpy of 65.41 J/g (Figure 1A, Table 1). Also, the addition of SA 246
onto SiNP surface shifted the exothermic peak to higher temperatures, in comparison to 247
SA alone. The shift of melting point and the exothermic peak in SiNP-SA may ascribe 248
to the interaction between silica and sodium alginate resulting in higher thermal stability 249
of the system. The second endothermic peak, at 253.51 °C, was attributed to the 250
removal of the absorbed water in the sample under heating. 251
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252
[Please, insert Figure 1 near here]253
254
From the DSC results, Ins-SiNP-SA (Figure 1B and Table 1) showed the endothermic 255
peak at different temperature values comparing to that obtained with unloaded 256
nanoparticles (Figure 1A). The endothermic peak started at lower temperature,257
confirming that the presence of insulin changes the thermal behavior of nanoparticles 258
due to the interaction between the protein and the polymer.259
As indicated on Table 1, chitosan exhibits a sharp endothermic event, ascribing to the 260
melting peak around 88.94 ºC and an exothermic event at 304.03 ºC. The coating of 261
SiNP with chitosan (Figure 1A) changed the thermal behavior of the polymer with 262
respect to the bulk material, shifting the endothermic transition to higher temperatures 263
(93.05 °C), indicating the formation of strong hydrogen bonding between silica and 264
chitosan [24]. To note, the exothermic peak of chitosan disappeared. Upon insulin 265
association to SiNP-CH (Figure 1B), the endothermic peak is still present, almost 266
unmodified. It can be concluded that the coating of SiNP with chitosan resulted in 267
higher stability of the system, requiring more energy to break the interactions between 268
silica and the polymer, as well as during the thermal decomposition of the nanoparticles. 269
Again, the second endothermic peak at 204.98 ºC observed after coating with chitosan 270
was due to the removal of adsorbed water. No signal of insulin peak was detectable after 271
its incorporation in SiNP-CH, suggesting that insulin is completely dissolved in the 272
polymer chains leading to an interaction between insulin and the polyelectrolyte (Figure 273
1; Table 1).274
Concerning the effect of PEGylation on SiNP, the thermal behavior of nanoparticles 275
using PEG 6000 was similar to that using PEG 20000 (Figure 1A). Pure PEG 6000 and 276
PEG 20000 melt at 63.04 and 54.43 ºC, respectively (Table 1). The coating of SiNP 277
with PEG 6000 and PEG 20000 shifted the endothermic peaks of the polymers to higher 278
temperatures about 83.41 ºC and 94.84 ºC, respectively (Figure 1A). This result was279
attributed to the fact that PEG chains, in PEG-SiNP, are less flexible than those in pure 280
PEG due to the interaction between silica and PEG segments (Figure 1A, Table 1). 281
SiNP could act as nucleating agent, promoting the orientation of PEG chains and 282
consequently leading to the high formation of crystal. In the presence of insulin, the 283
endothermic peaks were registered at 92.10 °C for Ins-SiNP-PEG 6000 (Figure 1B) and 284
at 102.17 °C for Ins-SiNP-PEG 20000 (Figure 1B). However, the peak recorded around 285
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50 ºC, observed in both formulations, can be related to the transition midpoint (Tm) of 286
insulin. Tm of insulin in the absence of nanoparticles was found to be 77.64 ºC (data not 287
shown). Therefore, it is clear that PEG decreased the thermal stability of insulin. These 288
results are in agreement with other studies that indicate that PEGs interact with the 289
protein molecules by hydrophobic interactions being responsible for the destabilization 290
of the protein structure [25].291
292
3.2. X-ray studies293
294
X-ray diffraction spectra indicate that sodium alginate, chitosan, PEG 6000, and PEG 295
20000 are present as a crystalline material (data not shown). However, the intensity of 296
the peaks in SiNP-coated with the polymers is decreased, reflecting less ordered 297
structure of the nanoparticles (Figures 2A). The association of insulin to nanoparticles 298
also supports high crystallinity of the nanoparticles in comparison to unloaded 299
nanoparticles (Figures 2B). The solubilization of insulin into the polymer solutions may 300
have a tendency to crystallize the formulations during storage, thus leading to a change 301
in the physical properties of the nanoparticles.302
303
[Please, insert Figure 2 near here]304
305
3.3. FTIR analysis306
307
Figure 3 shows the FTIR spectra relative to the Ins-SiNP-CH (a), Ins-SiNP-SA (b), Ins-308
SiNP-PEG 6000 (c), Ins-SiNP-PEG 20000 (d) and Ins-SiNP (e). 309
The FTIR spectra of Ins-SiNP (Figure 3 (e)) showed a peak of free O–H stretching 310
vibration around 3500 cm1 (H-bonded H2O, hydroxyl terminals, H-bonded OH 311
vibrations of alcohol and H-bonded Si–OH in chain), a peak of Si–O stretching 312
vibration around 1040 cm1, a peak Si-OH at 980 cm1, and a peak of Si–O–Si bending 313
around 600 cm1 vibration [26, 27].314
The spectra of Ins-SiNP-CH (Figure 3 (a)) showed the presence of peaks around 1600, 315
1500 and 1400 cm1, related to amide bond, to vibration of protonated amine group and 316
–CH2 bending, respectively. The absorption bands at 1000 cm
1 (skeletal vibrations 317
involving the C–O stretching) are characteristics of its saccharide structure [28]. A 318
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characteristic band at 3440 cm1 was assigned to O–H stretching, indicating 319
intermolecular hydrogen bonding which is overlapped in the same region to the 320
stretching vibration of N–H. 321
The bands around 1600 and 1400 cm1 present in the FTIR spectrum of Ins-SiNP-SA 322
Figure 3 (b) are assigned to symmetric and asymmetric stretching vibrations of 323
carboxylate salt groups. In addition, the bands around 1300 cm1 (C–O stretching), 1100 324
cm1 (C–C stretching) and 1000 cm1 (C–O stretching) are attributed to its saccharide 325
structure [29].326
The representative FTIR spectra of Ins-SiNP-PEG 20000 (Figure 3 (c)) and Ins-SiNP-327
PEG 6000 (Figure 3 (d)) were quite similar. The region between 3300 and 3600 cm1328
corresponds to O–H stretching, the band ranging from 2800 to 2900 cm1 corresponds 329
to C–H stretching and the band between 1000 and 1200 cm1 is assigned to C–O 330
stretching. The addition of PEG increased the relative intensity of the OH band 331
indicating the increase of degree of hydration of the samples [30].332
333
[Please, insert Figure 3 near here]334
335
Comparing the spectra, changes observed in the absorption band of O–H can be 336
assumed as a possible interaction that would occur between OH groups of SiNP and OH 337
groups of PEG, as well as between OH groups and carboxyl of alginate or amino groups 338
of chitosan. These results suggest an effective interaction between silica and the 339
polymers. Finally, a band indicative of amide I at 1645 cm1 (C=O stretching) was 340
observed in all samples, which is characterized by the presence of α-helical content 341
[31].342
343
3.4. In vitro cytotoxicity assay344
345
In this study, the toxicity of the different nanoparticles was evaluated by the resazurin 346
(Alamar Blue, AB) reduction assay using HepG2 and Caco-2 cell lines and results of 347
cell viability are compared with those of non-exposed cells (control) in terms of % of 348
control. Most authors consider that viability above 70% of the control is an indication of 349
“no toxicity” or of a safe material, and only viability below 70% is considered toxic, as 350
reviewed recently [32].351
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Caco-2 and HepG2 were exposed for 48 h to SiNP, to coated-SiNP and to insulin 352
loaded coated-SiNP, and the obtained results are shown in the Figures 4, 5 and 6.353
For the uncoated SiNP, cell viability ranged from 97.67 ± 0.19 % (for 50 µg/mL) to 354
108.97 ± 2.17 % (for 200 µg/mL) for Caco-2 cells (Figure 4A), and from 92.63 ± 1.04 355
% (for 50 µg/mL) to 101.45 ± 3.41 % (for 200 µg/mL) for HepG2 cells (Figure 4B). No 356
statistical significant changes, compared with the control group, were observed in both 357
cell lines and at all tested concentrations, after 48 h exposure to uncoated SiNP (p> 358
0.05). These results can be attributed to the surface charge of nanoparticles. In th s case, 359
SiNP have negative charge at pH 7. Several studies have reported that negatively360
charged nanoparticles exert very little or no toxicity on biological membranes, in 361
comparison to positively charged particles [33]. In Figure 4, a slight decrease in cell 362
viability is observed when cells are exposed to insulin-loaded nanoparticles, compared 363
to control. The decrease is more evident in Caco-2 cells (Figure 4A) than in HepG2364
cells (Figure 4B), but the differences are minimal (no more than a 10% of decrease, 365
from control).366
367
[Please, insert Figure 4 near here]368
369
It is important to consider that the coating of the nanoparticles with chitosan (CH), 370
sodium alginate (SA) or PEG may change the pattern of toxicity comparing with the 371
free polymers. For SiNP coated with chitosan, the cell viability ranged from 76.68 ± 372
1.17 % (for 500 µg/mL) to 96.84 ± 0.97 % (for 50 µg/mL) for Caco-2 cell (Figure 5A) 373
and from 85.99 ± 8.99 % (for 200 µg/mL) to 99.44 ± 2.91 % (for 50 µg/mL) for HepG2 374
cells (Figure 5B). As shown in Figure 5A, compared with the control group, all 375
concentrations reduced significantly the cell viability (p < 0.05), although reduction in 376
not higher than 25 %. Figure 5A also shows that cell viability is reduced with the 377
increase in the nanoparticles concentration, leading to cytotoxicity being concentration 378
dependent, and that loading SiNP-CH with insulin improves cell viability.379
As observed in Figure 5B, HepG2 cell viability was less affected by nanoparticles 380
exposure than Caco-2 cells. At 50 μg/mL SiNP-CH, changes in cell viability were not 381
statistically significant, after 48 h exposure. Comparing with uncoated SiNP (Figure 4), 382
it is observed that SiNP coated with chitosan (SiNP-CH) induced slightly higher 383
toxicity in both cell lines (Figure 5A and B). In vitro evaluation of chitosan and chitosan 384
nanoparticles has been performed in a wide range of cell lines demonstrating low 385
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cytotoxicity [34, 35]. However, it is known that cationic compounds can cause cell 386
damage. The presence of the positive charges on the SiNP-CH surface may387
consequently affects the interaction with cells leading to a decrease of cell viability. 388
Many studies suggest that cationic materials imply higher toxicity due to the 389
interactions with the plasmatic membrane and/or with negatively charged cell 390
components and proteins [36-38]. Also, some works have showed that chitosan coated 391
nanoparticles can induce cell apoptosis in some extend [39].392
As observed in Figure 5A and 5B, insulin-loaded nanoparticles decreased the 393
cytotoxicity of SiNP-CH, after 48 h of exposure, being more evident in Caco-2 cells at 394
high concentrations. This phenomenon can be related to the possible decrease of the 395
interaction between the positively charged amino groups of chitosan with the anionic 396
components of the glycoproteins on the cell membrane surface, improving cell viability.397
Regarding to SiNP-SA, Caco-2 cells (Figure 5C) were also more susceptible than 398
HepG2 cells (Figure 5D) to the exposure to SiNP-coated with sodium alginate. All 399
concentrations of SiNP-SA significantly reduced the viability of Caco-2 cells, compared 400
to control (Figure 5C), however, some reductions are minimal (no more than a 20% of 401
decrease, from control). However, only the concentration of 500 µg/mL of SiNP-SA 402
reduced significantly HepG2 viability (Figure 5D). Similar results were obtained by 403
Douglas and co-workers [40], demonstrating that high concentrations of alginate-404
chitosan nanoparticles resulted in a significant decrease of 293 T cells viability after 24 405
h of incubation in comparison to chitosan polymer.406
407
[Please, insert Figure 5 near here]408
409
After insulin incorporation into SiNP-SA, all tested concentrations showed low 410
cytotoxicity in Caco-2 (Figure 5C) and HepG2 cells (Figure 5D). As reported411
previously, insulin loading seems to improve cell viability. These results are in evident 412
agreement with other studies demonstrating high biocompatibility of alginate as a 413
coating or even as a carrier [41]. 414
In general, we can observe a low degree of toxicity for all particles at the concentration 415
range tested. However, for the unloaded nanoparticles, a reduction in the cell viability is 416
observed which is concentration dependent, and it is more evident for Caco-2 cells, as 417
observed for SiNP-CH (Figure 5A) and for SiNP-SA (Figure 5C).418
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Concerning the coating with PEG (Figure 6), two different PEG polymers were studied 419
differing in chain extent and thus in MW, the PEG 6000 and PEG 20000 were used. 420
Cell viability of Caco-2 (Figure 6A) and HepG2 cells (Figure 6B) after 48 h of exposure 421
to SiNP-PEG 6000 and SiNP-PEG 20000 is shown. Concerning the effect of 422
nanoparticles concentration on cytotoxicity, we could note that higher concentrations of 423
SiNP-PEG 6000 (200 and 500 µg/mL) induced higher cytotoxicity in both cell lines 424
(Figure 6A and 6B), to note that 500 µg/mL of SiNP-PEG 6000 reduced Caco-2 cell 425
viability by more than 50% (Figure 6A). However, according to what has been already 426
reported insulin-loading improves cell viability, and for all concentrations of Ins-SiNP-427
PEG 6000 viability is around 90%. 428
On the other hand, SiNP-PEG 20000 did not significantly affect the HepG2 or the Caco-429
2 cell viability (Figure 6B and 6A). In general, conjugation of PEG to nanoparticles is 430
recognized as being nontoxic by all routes of administration. However, comparing to 431
uncoated SiNP, the concentrations of 200 and 500 µg/mL of SiNP-PEG 6000, in both 432
cell lines, reduced significantly cell viability. Cho and co-workers [42] showed that gold 433
nanoparticles coated with PEG 5000 can induce acute inflammation and apoptosis in the 434
mouse liver. Higher cell viability, especially at concentration of 200 and 500 µg/mL 435
was observed for SiNP-PEG 20000 compared to that of SiNP-PEG 6000. This result 436
can be attributed to the long chain structure of PEG 20000 leading to a higher steric 437
effect. The flexibility of a long PEG chain like PEG 20000 was supposed to make it to438
cover greater surface area. Similar observations were obtained by Mao and co-workers 439
[43] that verified lower cytotoxicity effect of trimethyl chitosan (TMC) grafted by PEG 440
5 kDa in comparison to TMC grafted by PEG 550 Da. However, some studies showed 441
that low PEG chain length used for poly(ethylene imine) (PEI) coating induced low442
cytotoxic and oxidative stress response in lung cell line [44]. No cytotoxicity effect on 443
cell proliferation and viability was observed after the incorporation of insulin into SiNP-444
PEG 6000 and SiNP-PEG 20000 for both cell lines (Figure 6).445
446
4. Conclusions447
448
DSC, X-ray and FTIR were used to evaluate the influence of different coatings in 449
insulin-loaded SiNP. In the DSC studies, the endothermic and exothermic peaks of pure 450
polymers were shifted to high temperature in all coated SiNP resulting in more stable 451
systems. The X-ray diffraction showed that coated SiNP displayed less ordered 452
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structure compared with pure polymers. On the other hand, the association of insulin to 453
nanoparticles resulted in more crystalline structures. FTIR analysis also demonstrated 454
the interaction between mucoadhesive polymers and nanoparticles. Additionally, the 455
toxicity assay showed that different surface modification of SiNP did not affect, or 456
affect in a low degree, the cell viability, demonstrating very low toxicity in Caco-2 and 457
HepG2 cell lines, indicating that the developed nanoparticles are promising 458
biocompatible for oral drug delivery systems.459
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603
Figure Caption604
605
Figure 1. DSC thermograms. (A) SiNP coated with sodium alginate (SA), chitosan 606
(CH), PEG 6000 or PEG 20000, as indicated. (B) SiNP coated with sodium alginate 607
(SA), chitosan (CH), PEG 6000 or PEG 20000 after insulin association, as indicated.608
609
Figure 2. X-ray diffraction patterns of (A) SiNP coated with sodium alginate (SA),610
chitosan (CH), PEG 6000 or PEG 20000; (B) of SiNP coated with sodium alginate 611
(SA), chitosan (CH), PEG 6000 or PEG 20000 after insulin association, as indicated.612
613
Figure 3. FTIR spectra of (a) Ins-SiNP-CH, (b) Ins-SiNP-SA, (c) Ins-SiNP-PEG 20000, 614
(d) Ins-SiNP-PEG 6000 and (e) Ins-SiNP.615
616
Figure 4. Viability of Caco-2 (A) and HepG2 (B) cells after 48 h exposure to 50, 100, 617
200 and 500 μg/mL of uncoated and unloaded SiNP, (white bars) and uncoated insulin-618
loaded (grey bars). Cell viability is expressed as % of control, being the mean of 3 619
different experiments ± S.D.. For each cell line, three independent experiments (each 620
with 8 replicates) were carried out.621
622
Figure 5. Effect of coating SiNP with chitosan (CH) or sodium alginate (SA) on cell 623
viability.Caco-2 cells (A) and HepG2 cells (B) were exposed to empty chitosan coated 624
SiNP (SiNP-CH; white bars) and to insulin loaded SiNP-CH (Ins-SiNP-CH; dark-grey 625
bars). In different experiments, Caco-2 cells (C) and HepG2 cells (D) were exposed to 626
SA-coated empty SiNP (SiNP-SA; light grey bars) or to insulin-loaded SiNP-SA(Ins-627
SiNP-SA; black bars). All cells were exposed to the respective NP for 48 h at 50, 100, 628
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200 and 500 μg/mL, as denoted. Cell viability is expressed as % of control, being the 629
mean of 3 different experiments ± S.D. For each cell line, three independent 630
experiments (each with 8 replicates) were carried out. 631
632
Figure 6. Effect of PEGylation of SiNP on the cell viability of Caco-2 (A) and HepG2 633
(B) cells using PEG 6000 and PEG 20000, as indicated. Cells were exposed for 48 h to 634
50, 100, 200 and 500 μg/mL with coated-SiNP and insulin-loaded coated-SiNP, as 635
denoted. Cell viability is expressed as % of control being the mean of 3 different 636
experiments ± S.D. For each cell line, three independent experiments (each with 8 637
replicates) were carried out.638
639
640
641
Table Caption642
643
Table 1.DSC parameters of the polymers and unloaded and loaded-nanoparticles644
produced by sol-gel technology.645
646
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Table Caption646
647
Table 1. DSC parameters of the polymers and unloaded and loaded-nanoparticles648
produced by sol-gel technology.649
650
Table 1.651
Temperature  
(ºC)
Samples
Initial        Peak  Final
ΔH (J/g)
PEG 6000 58.50 63.04 73.57 163.40
PEG 20000 51.97 54.43 62.95 101.70
Sodium alginate 43.99 97.00 153.31 238.00
220.78 239.74 273.67 202.70
Chitosan 45.17 88.94 139.72 124.40
286.32 304.03 338.78 117.00
SiNP-PEG 6000 32.05 83.41 133.08        89.24
268.72 287.30 347.28 145.40
SiNP-PEG 20000 40.84 94.84 159.43 123.40
263.37 287.89 347.07 209.60
SiNP-SA 77.65 139.91 199.85        65.41
210.11 253.51 279.06        26.69
282.50 311.55 345.00 120.10
SiNP-CH 40.09 93.05 155.48        94.81
201.29 229.84 306.84 126.20
Ins-SiNP-PEG 6000 59.63 92.10 114.01 128.70
Ins-SiNP-PEG 20000 69.28 101.17 142.21 146.10
Ins-SiNP-SA 78.23 102.16 129.77 132.30
287.90 292.99 297.72        53.43
Ins-SiNP-CH 53.41 91.29 150.92 234.80
193.02 204.98 230.12 133.30
652
653
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1) Hybrid nanoparticles were produced by Stöber method for insulin association653
2) Silica nanoparticles were coated with chitosan, sodium alginate or PEG654
3) Coating of silica nanoparticles resulted in more stable systems655
4) PEGylated nanoparticles decreased the thermal stability of insulin656
5) In general, all nanoparticles showed low toxicity in Caco-2 and HepG-2 cells657
658
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